	US 11,702,474 B2
	Antibodies specific for CD47, PD-L1, and uses thereof
Javier Fernando Chaparro Riggers, San Mateo, CA (US); Shih-Hsun Chen, San Diego, CA (US); Sheng Ding, Foster City, CA (US); Pawel Kamil Dominik, San Diego, CA (US); Shahram Salek-Ardakani, La Jolla, CA (US); Jessica Lynn Stanfield, San Diego, CA (US); and Thomas John Van Blarcom, Oakland, CA (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Dec. 14, 2020, as Appl. No. 17/120,935.
Claims priority of provisional application 63/110,693, filed on Nov. 6, 2020.
Claims priority of provisional application 62/949,120, filed on Dec. 17, 2019.
Prior Publication US 2021/0179716 A1, Jun. 17, 2021
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

27 Claims

1. An isolated antibody that specifically binds to CD47 and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises (i) a VH complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 13, 14, or 15; (ii) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16 or 17; (iii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 18; (iv) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 19; (v) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 20; and (vi) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 21.